straitstimes.com -- The pharmaceutical industry in Singapore has moved into higher gear, with the opening of a state-of-the-art $600 million GlaxoSmithKline (GSK) vaccine plant in Tuas. The plant will be able to produce biologic drugs, which use natural products like blood or bacteria, and Singapore is one of the few countries in the world which has this capability.
